OncoMatch/Clinical Trials/NCT07427043

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

Is NCT07427043 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including multimodal analgesia pathway with up-front small opioid prescription and multimodal analgesia pathway without up-front small opioid prescription for opioid consumption, postoperative.

Treatment: multimodal analgesia pathway with up-front small opioid prescription · multimodal analgesia pathway without up-front small opioid prescription · pre-implementation baseline including opioid — This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then may opt into or out of the study with randomization to discharge prescriptions including (A) multimodal plan with additional automatic opioid prescription or (B) multimodal plan alone and instruction to call phone line to request opioid prescription if pain management is insufficient. Additionally, a cohort of historical controls prior to implementation of the study is also prospectively assessed as a pre-study baseline. The primary outcome is postoperative opioid consumption. Secondary outcomes include bowel function recovery, unplanned care encounters including emergency department visits or postoperative phone calls, and same-day discharge rates.